NSF award 2514128 · Stanford University

BRING-SynBio: Proteolytic Dosage Control of Protein Circuits to Modulate Intercellular Communications

Final report due

29 December 2027

in 437 days · The award ends on 31 August 2027.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension3 May 2027in 197 days
award ending 2027-08-31 · Research.gov
This one is ours, not NSF’s.
Extension request17 Jul 2027in 272 days
award ending 2027-08-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 Aug 2027in 307 days
award ending 2027-08-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due29 Dec 2027in 437 days
award ending 2027-08-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due29 Dec 2027in 437 days
award ending 2027-08-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out29 Dec 2027in 437 days
award ending 2027-08-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 August 2027.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 29 December 2027.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2514128
Period of support: 1 Sep 2025 – 31 Aug 2027
Amount: $300,000
Awardee: Stanford University, Stanford, CA
Program: Cellular & Biochem Engineering
Directorate: ENG

Abstract

Synthetic biology can be used to create and improve treatments for many diseases. Genetic techniques are used to modify T cells to create CAR-T cells that can kill some types of cancer cells. Gene therapy offers the promise of curing genetic diseases for which there are no treatments. A significant problem with these technologies is the variability of gene delivery to the targeted cells. Viral particles are often…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.